Bionano Genomics Reports Third Quarter 2022 Financial Results and Highlights Recent Business Progress
Retrieved on:
Thursday, November 3, 2022
Chronic lymphocytic leukemia, DNA, Society, Potency (pharmacology), IPSC, Cerebellar ataxia, BMA, Regenerative medicine, MD Anderson Cancer Center, Schizophrenia, CRISPR, Company, Infertility, Workflow, Study, Growth, SAN, GAAP, OGM, GLOBE, Total, Ataxia, Genomics, LDT, ASHG, Chromothripsis, Patient, Cancer, CLL, Doctor of Philosophy, MDS, Long, SVS, Research, Hospital, Human genetics, Lineagen, Sale, International Cancer Genome Consortium, Pregnancy loss, NIPT, CTH, Adoption, Long-string instrument, UHMW, American Society of Human Genetics, Chromosome, ATM, RPL, Industry, Microdeletion syndrome, Publication, Certification, Tumors of the hematopoietic and lymphoid tissues, Acute myeloid leukemia, Nasdaq, Peripheral neuropathy, Karyotype, TP53, AML, RFC1, Renewable energy, Video game, Pharmaceutical industry, Medical imaging
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September 30, 2022.
Key Points:
- milestones
Strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities at the end of Q3 2022
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September30, 2022. - We believe our Q3 2022 results, which include the highest quarterly revenues ever for Bionano, reflect continued gains in market development and commercial validation for OGM.
- Total revenue for Q3 2022 was $7.2 million, up 55% from Q3 2021, and an 8% increase from Q2 2022.
- Chris Stewart, chief financial officer of Bionano added, Q3 2022 was another outstanding quarter for Bionano.